CRAD001T2302: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - RADIANT-4
To learn if everolimus is safe and effective for subjects who have advanced Neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin.
Advanced NET of GI or lung origin
1. Male or female aged 18 or older
2. Confirmed neuroendocrine tumor of GI or lung origin.
3. No history of and no active symptoms related to carcinoid syndrome.
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will continue to take the study drug as long as you benefit from it, until you experience intolerable side effects, or until you withdraw your consent.
Caron Campbell, RN